-+ 0.00%
-+ 0.00%
-+ 0.00%

CARDIFF ONCOLOGY - ONVANSERTIB BEING EVALUATED IN PHASE 1 STUDY FOR RELAPSED/REFRACTORY CMML

Reuters·10/21/2026 20:05:00

Please log in to view news